SAR 445399
Alternative Names: Anti-IL1R3 mAb - Sanofi; MAB-212; SAR-445399Latest Information Update: 28 Jan 2026
At a glance
- Originator MAB Discovery; Sanofi
- Developer Sanofi
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Interleukin-1 receptor accessory protein modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hidradenitis suppurativa
- Phase I Inflammation
Most Recent Events
- 29 Dec 2025 Phase-II clinical trials in Hidradenitis suppurativa (Treatment-resistant) in USA (Parenteral, Infusion) (NCT07225569)
- 29 Dec 2025 Phase-II clinical trials in Hidradenitis suppurativa (Treatment-resistant) in USA (Parenteral, Injection) (NCT07225569)
- 06 Nov 2025 Sanofi plans a phase II CLAROS trial for Hidradenitis suppurativa in Hungary (Parenteral, Injection/infusion) in December 2025 (NCT07225569)